Ceribell: Expanding Neurology Platform, Growing TAM, and Attractive Valuation Support Buy Rating

William Blair analyst Brandon Vazquez has maintained their bullish stance on CBLL stock, giving a Buy rating on January 5.

Brandon Vazquez has given his Buy rating due to a combination of factors that point to a strong, multi-layered growth outlook for Ceribell. He expects the recently expanded salesforce to keep accelerating penetration in the core adult seizure market, while the company simultaneously begins to capture incremental demand from new pediatric and neonatal use cases. Vazquez also highlights that the technology is evolving beyond seizures, with cleared use in delirium and breakthrough designation for large-vessel-occlusion stroke, positioning the system as a broader neurological monitoring and AI platform. In his view, the company’s demonstrated ability to enlarge its addressable market validates execution capabilities and supports confidence in future growth catalysts.

At the current valuation of roughly seven times his 2026 revenue forecast, Vazquez believes the stock does not fully reflect Ceribell’s long-term potential. He anticipates that sustained sales momentum, driven by both deeper adoption in existing indications and expansion into new clinical areas, will be the primary engine of share appreciation. This combination of near-term commercialization progress, pipeline optionality in additional indications, and what he views as an attractive entry multiple underpins his Outperform (Buy) recommendation on Ceribell. Overall, he sees a favorable risk-reward profile supported by execution to date and visible avenues for continued top-line growth.

In another report released on January 5, TD Cowen also maintained a Buy rating on the stock with a $29.00 price target.